摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Hydroxy-3-[4-(5-phenylpentylsulfanyl)phenoxy]propanenitrile | 273939-27-8

中文名称
——
中文别名
——
英文名称
2-Hydroxy-3-[4-(5-phenylpentylsulfanyl)phenoxy]propanenitrile
英文别名
——
2-Hydroxy-3-[4-(5-phenylpentylsulfanyl)phenoxy]propanenitrile化学式
CAS
273939-27-8
化学式
C20H23NO2S
mdl
——
分子量
341.474
InChiKey
LQTHZQSYFVUMHN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    24
  • 可旋转键数:
    10
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    78.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Hydroxy-3-[4-(5-phenylpentylsulfanyl)phenoxy]propanenitrile盐酸 作用下, 以 乙腈 为溶剂, 生成 2-((2-(1-hydroxy-2-(4-((5-phenylpentyl)thio)phenoxy)ethyl)-1H-benzo[d]imidazol-6-yl)oxy)acetic acid
    参考文献:
    名称:
    Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap
    摘要:
    We report the design of novel, potent cPLA(2)alpha inhibitors that possess an alpha-methyl-2-ketothiazole that acts as a serine-reactive moiety. We describe the optimization of the series for potency and metabolic stability towards ketone reduction. This was achieved by attenuating the reactivity of the ketone using a combination of electronic and steric effects. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.03.005
  • 作为产物:
    描述:
    Ethyl 2-[4-(5-phenylpentylsulfanyl)phenoxy]acetate 在 二异丁基氢化铝三乙胺 作用下, 以 四氢呋喃 为溶剂, 生成 2-Hydroxy-3-[4-(5-phenylpentylsulfanyl)phenoxy]propanenitrile
    参考文献:
    名称:
    Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap
    摘要:
    We report the design of novel, potent cPLA(2)alpha inhibitors that possess an alpha-methyl-2-ketothiazole that acts as a serine-reactive moiety. We describe the optimization of the series for potency and metabolic stability towards ketone reduction. This was achieved by attenuating the reactivity of the ketone using a combination of electronic and steric effects. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.03.005
点击查看最新优质反应信息

文献信息

  • NOVEL COMPOUNDS
    申请人:AstraZeneca AB
    公开号:EP1135377A1
    公开(公告)日:2001-09-26
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
    申请人:ASTRAZENECA UK LTD
    公开号:WO2000034254A1
    公开(公告)日:2000-06-15
    Compounds of formula (I) are disclosed, processes for their preparation, pharmaceutical compositions containing the compounds and the use of the compounds as pharmaceuticals. There are also provided chemical intermediates useful for the preparation of the compounds. The compounds are useful as pharmaceuticals, especially for the treatment of inflammatory disease.
  • Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap
    作者:Antonio Mete、Glen Andrews、Mike Bernstein、Stephen Connolly、Paul Hartopp、Clive G. Jackson、Richard Lewis、Iain Martin、David Murray、Rob Riley、David H. Robinson、Gill M. Smith、Edward Wells、W. John Withnall
    DOI:10.1016/j.bmcl.2011.03.005
    日期:2011.5
    We report the design of novel, potent cPLA(2)alpha inhibitors that possess an alpha-methyl-2-ketothiazole that acts as a serine-reactive moiety. We describe the optimization of the series for potency and metabolic stability towards ketone reduction. This was achieved by attenuating the reactivity of the ketone using a combination of electronic and steric effects. (C) 2011 Elsevier Ltd. All rights reserved.
查看更多